Psychopharmacology of autism spectrum disorders and other related comorbidities

Eric C. Alcera; Michelle Jaehning; Ramon Solhkhah

doi:10.1016/B978-0-323-85031-5.00021-9

Psychopharmacology of autism spectrum disorders and other related comorbidities

Eric C. Alcera
, Michelle Jaehning
, Ramon Solhkhah

School of Medicine

Jersey Shore University Medical Center
Hackensack Meridian School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Autism spectrum disorder (ASD) and the use of medications in its treatment continue to evolve as its prevalence trends upward. Many psychiatrists face challenges in determining the correct balance of medications and other evidence-based treatments. Psychopharmacology remains an important treatment intervention in addressing the accompanying disorders related to this syndrome. This chapter will serve as a guideline for the current psychopharmacologic agents utilized in clinical practice, centered on medications supported by literature and research.

Original language	English
Title of host publication	Emerging Programs for Autism Spectrum Disorder
Subtitle of host publication	Improving Communication, Behavior, and Family Dynamics
Publisher	Elsevier
Pages	303-335
Number of pages	33
ISBN (Electronic)	9780323850315
DOIs	https://doi.org/10.1016/B978-0-323-85031-5.00021-9
State	Published - 1 Jan 2021

Keywords

ASD
Autism
Psychopharmacology

Access to Document

10.1016/B978-0-323-85031-5.00021-9

Cite this

@inbook{f0a8577564a94b6199cfa320985ea9f7,

title = "Psychopharmacology of autism spectrum disorders and other related comorbidities",

abstract = "Autism spectrum disorder (ASD) and the use of medications in its treatment continue to evolve as its prevalence trends upward. Many psychiatrists face challenges in determining the correct balance of medications and other evidence-based treatments. Psychopharmacology remains an important treatment intervention in addressing the accompanying disorders related to this syndrome. This chapter will serve as a guideline for the current psychopharmacologic agents utilized in clinical practice, centered on medications supported by literature and research.",

keywords = "ASD, Autism, Psychopharmacology",

author = "Alcera, \{Eric C.\} and Michelle Jaehning and Ramon Solhkhah",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-85031-5.00021-9",

language = "English",

pages = "303--335",

booktitle = "Emerging Programs for Autism Spectrum Disorder",

publisher = "Elsevier",

}

TY - CHAP

T1 - Psychopharmacology of autism spectrum disorders and other related comorbidities

AU - Alcera, Eric C.

AU - Jaehning, Michelle

AU - Solhkhah, Ramon

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Autism spectrum disorder (ASD) and the use of medications in its treatment continue to evolve as its prevalence trends upward. Many psychiatrists face challenges in determining the correct balance of medications and other evidence-based treatments. Psychopharmacology remains an important treatment intervention in addressing the accompanying disorders related to this syndrome. This chapter will serve as a guideline for the current psychopharmacologic agents utilized in clinical practice, centered on medications supported by literature and research.

AB - Autism spectrum disorder (ASD) and the use of medications in its treatment continue to evolve as its prevalence trends upward. Many psychiatrists face challenges in determining the correct balance of medications and other evidence-based treatments. Psychopharmacology remains an important treatment intervention in addressing the accompanying disorders related to this syndrome. This chapter will serve as a guideline for the current psychopharmacologic agents utilized in clinical practice, centered on medications supported by literature and research.

KW - ASD

KW - Autism

KW - Psychopharmacology

UR - https://www.scopus.com/pages/publications/85127132119

U2 - 10.1016/B978-0-323-85031-5.00021-9

DO - 10.1016/B978-0-323-85031-5.00021-9

M3 - Chapter

AN - SCOPUS:85127132119

SP - 303

EP - 335

BT - Emerging Programs for Autism Spectrum Disorder

PB - Elsevier

ER -

Psychopharmacology of autism spectrum disorders and other related comorbidities

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this